prostate cancer

Is This Tiny Aussie Biotech the Next Dendreon?

Dendreon's Provenge, which targets prostate cancer, catapulted that company's stock to record highs recently. Prima Biomed's CVac works similarly, but it has the potential to target multiple forms of cancer, giving the Australian company an intriguing future.

Dendreon Shares Slide on Medicare Payment Worries

The stock sank on Thursday after the Centers for Medicare and Medicaid Services said it was evaluating data on Provenge, the company's prostate cancer vaccine, to decide whether to cover the drug for seniors nationwide.

Experts Face Off on Prostate Cancer Drugs

If you could prevent cancer by taking a pill, would you? Probably. Should you? That's a matter of debate among doctors. Merck's Proscar and now GlaxoSmithKline's Avodart have been shown in stidues to cut prostate cancers. But whether those studies are conclusive is the question.